Hydrocortisone (Topical)
Brand names: Hc45, Dioderm
Topical hydrocortisone is a mild corticosteroid applied to the skin for mild inflammatory dermatoses such as eczema, dermatitis and insect-bite reactions.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It activates glucocorticoid receptors in skin cells to reduce inflammatory mediator release, producing local anti-inflammatory and antipruritic effects.
Prescribing in practice
- Although low potency, avoid prolonged use on the face and flexures and limit application in infants, as even mild steroids can cause local skin thinning with excessive use.
- Do not apply to untreated infected skin, acne or rosacea.
- Some low-strength preparations are available for short-term use over the counter for limited indications and body sites.
Monitoring
Review response after a short course and reassess if the rash fails to settle or appears infected.
Counselling the patient
- Apply a thin layer to affected areas, typically once or twice daily, for a short period.
- Avoid the eyes and only use on the face if specifically advised.
- Keep using emollients alongside to maintain the skin barrier.
Evidence & guidelines
Mild topical corticosteroids such as hydrocortisone are first-line for mild eczema flares in line with NICE eczema guidance.
Reference: NICE NG190 Atopic Eczema; British Association of Dermatology (BAD) Guidelines; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD